File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: A population-based study in Hong Kong

TitleThree-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: A population-based study in Hong Kong
Authors
Issue Date2022
PublisherThe Lancet. The Journal's web site is located at https://www.thelancet.com/regional-health/western-pacific
Citation
The Lancet Regional Health - Western Pacific, 2022, p. 100660 How to Cite?
AbstractBackground The ongoing outbreak of SARS-CoV-2 Omicron BA.2 infections in Hong Kong, the model city of universal masking of the world, has resulted in a major public health crisis. Although the third vaccination resulted in strong boosting of neutralization antibody, vaccine efficacy and correlate of immune protection against the major circulating Omicron BA.2 remain to be investigated. Methods We investigated the vaccine efficacy against the Omicron BA.2 breakthrough infection among 470 public servants who had received different SARS-CoV-2 vaccine regimens including two-dose BNT162b2 (2 × BNT, n = 169), threedose BNT162b2 (3 × BNT, n = 168), two-dose CoronaVac (2 × CorV, n = 34), three-dose CoronaVac (3 × CorV, n = 67) and third-dose BNT162b2 following 2 × CorV (2 × CorV+1BNT, n = 32). Humoral and cellular immune responses after threedose vaccination were further characterized and correlated with clinical characteristics of BA.2 infection. Findings During the BA.2 outbreak, 27.7% vaccinees were infected. The timely third-dose vaccination provided significant protection with lower incidence rates of breakthrough infections (2 × BNT 46.2% vs 3 × BNT 13.1%, p < 0.0001; 2 × CorV 44.1% vs 3 × CorV 19.4%, p = 0.003). Investigation of immune responses on blood samples derived from 90 subjects in three-dose vaccination cohorts collected before the BA.2 outbreak revealed that the third-dose vaccination activated spike (S)-specific memory B cells and Omicron cross-reactive T cell responses, which correlated with reduced frequencies of breakthrough infections and disease severity rather than with types of vaccines. Moreover, the frequency of S-specific activated memory B cells was significantly lower in infected vaccinees than uninfected vaccinees before vaccine-breakthrough infection whereas IFN-γ+ CD4 T cells were negatively associated with age and viral clearance time. Critically, BA.2 breakthrough infection boosted crossreactive memory B cells with enhanced cross-neutralizing antibodies to Omicron sublineages, including BA.2.12.1 and BA.4/5, in all vaccinees tested. Interpretation Our results imply that the timely third vaccination and immune responses are likely required for vaccine-mediated protection against Omicron BA.2 pandemic. Although BA.2 conferred the highest neutralization resistance compared with variants of concern tested before the emergence of BA.2.12.1 and BA.4/5, the third dosevaccination-activated S-specific memory B cells and Omicron cross-reactive T cell responses contributed to reduced frequencies of breakthrough infection and disease severity. Neutralizing antibody potency enhanced by BA.2 breakthrough infection in vaccinees with prior 3 doses of CoronaVac or BNT162b2 may reduce the risk of infection against ongoing BA.2.12.1 and BA.4/5.
Persistent Identifierhttp://hdl.handle.net/10722/324261

 

DC FieldValueLanguage
dc.contributor.authorZhou, R-
dc.contributor.authorLIU, N-
dc.contributor.authorLi, X-
dc.contributor.authorPENG, Q-
dc.contributor.authorYiu, CK-
dc.contributor.authorHuang, H-
dc.contributor.authorYang, D-
dc.contributor.authorDu, Z-
dc.contributor.authorKwok, HY-
dc.contributor.authorAu, KK-
dc.contributor.authorCai, J-
dc.contributor.authorHung, FNI-
dc.contributor.authorTo, KKW-
dc.contributor.authorXu, X-
dc.contributor.authorYuen, KY-
dc.contributor.authorChen, Z-
dc.date.accessioned2023-01-20T06:36:57Z-
dc.date.available2023-01-20T06:36:57Z-
dc.date.issued2022-
dc.identifier.citationThe Lancet Regional Health - Western Pacific, 2022, p. 100660-
dc.identifier.urihttp://hdl.handle.net/10722/324261-
dc.description.abstractBackground The ongoing outbreak of SARS-CoV-2 Omicron BA.2 infections in Hong Kong, the model city of universal masking of the world, has resulted in a major public health crisis. Although the third vaccination resulted in strong boosting of neutralization antibody, vaccine efficacy and correlate of immune protection against the major circulating Omicron BA.2 remain to be investigated. Methods We investigated the vaccine efficacy against the Omicron BA.2 breakthrough infection among 470 public servants who had received different SARS-CoV-2 vaccine regimens including two-dose BNT162b2 (2 × BNT, n = 169), threedose BNT162b2 (3 × BNT, n = 168), two-dose CoronaVac (2 × CorV, n = 34), three-dose CoronaVac (3 × CorV, n = 67) and third-dose BNT162b2 following 2 × CorV (2 × CorV+1BNT, n = 32). Humoral and cellular immune responses after threedose vaccination were further characterized and correlated with clinical characteristics of BA.2 infection. Findings During the BA.2 outbreak, 27.7% vaccinees were infected. The timely third-dose vaccination provided significant protection with lower incidence rates of breakthrough infections (2 × BNT 46.2% vs 3 × BNT 13.1%, p < 0.0001; 2 × CorV 44.1% vs 3 × CorV 19.4%, p = 0.003). Investigation of immune responses on blood samples derived from 90 subjects in three-dose vaccination cohorts collected before the BA.2 outbreak revealed that the third-dose vaccination activated spike (S)-specific memory B cells and Omicron cross-reactive T cell responses, which correlated with reduced frequencies of breakthrough infections and disease severity rather than with types of vaccines. Moreover, the frequency of S-specific activated memory B cells was significantly lower in infected vaccinees than uninfected vaccinees before vaccine-breakthrough infection whereas IFN-γ+ CD4 T cells were negatively associated with age and viral clearance time. Critically, BA.2 breakthrough infection boosted crossreactive memory B cells with enhanced cross-neutralizing antibodies to Omicron sublineages, including BA.2.12.1 and BA.4/5, in all vaccinees tested. Interpretation Our results imply that the timely third vaccination and immune responses are likely required for vaccine-mediated protection against Omicron BA.2 pandemic. Although BA.2 conferred the highest neutralization resistance compared with variants of concern tested before the emergence of BA.2.12.1 and BA.4/5, the third dosevaccination-activated S-specific memory B cells and Omicron cross-reactive T cell responses contributed to reduced frequencies of breakthrough infection and disease severity. Neutralizing antibody potency enhanced by BA.2 breakthrough infection in vaccinees with prior 3 doses of CoronaVac or BNT162b2 may reduce the risk of infection against ongoing BA.2.12.1 and BA.4/5.-
dc.languageeng-
dc.publisherThe Lancet. The Journal's web site is located at https://www.thelancet.com/regional-health/western-pacific-
dc.relation.ispartofThe Lancet Regional Health - Western Pacific-
dc.titleThree-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: A population-based study in Hong Kong-
dc.typeArticle-
dc.identifier.emailZhou, R: zhourh@hku.hk-
dc.identifier.emailLi, X: xinli@hku.hk-
dc.identifier.emailYiu, CK: yiuck@hku.hk-
dc.identifier.emailHuang, H: hao123@hku.hk-
dc.identifier.emailYang, D: yangdw@hku.hk-
dc.identifier.emailKwok, HY: hauyeek@hku.hk-
dc.identifier.emailAu, KK: akkit@hku.hk-
dc.identifier.emailCai, J: caijuice@hku.hk-
dc.identifier.emailHung, FNI: ivanhung@hkucc.hku.hk-
dc.identifier.emailTo, KKW: kelvinto@hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailChen, Z: zchenai@hku.hk-
dc.identifier.authorityZhou, R=rp03016-
dc.identifier.authorityLi, X=rp02808-
dc.identifier.authorityHung, FNI=rp00508-
dc.identifier.authorityTo, KKW=rp01384-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityChen, Z=rp00243-
dc.identifier.doi10.1016/j.lanwpc.2022.100660-
dc.identifier.hkuros343431-
dc.identifier.spage100660-
dc.identifier.epage100660-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats